ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO850

Study of T-Regulatory Cells and B-Regulatory Cells in Lupus Nephritis: A Prospective Observational Study

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Girimaji, Niveditha, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Gupta, Krishan Lal L., Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Ramachandran, Raja, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Rathi, Manish, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Rakha, Aruna, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Sharma, Aman, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
  • Duseja, Ritambhra Nada, Post Graduate Institute of Medical Education and Research,Chandigarh, Chandigarh, India
Background

Studies in lupus nephritis(LN) have shown impairment in both T regulatory(Treg) number and function.The data on B regulatory (Breg) is limited in LN. We conducted a prospective observational study of Treg and Breg populations in LN and their trend after initiation of immunosuppression.

Methods

Study included 20 patients of treatment-naïve LN of ISN/RPS Class III(±V),IV(±V),V and 10 healthy controls(HC). Immunophenotyping was performed for peripheral blood mononuclear cell samples using flurochrome labelled monoclonal antibodies for identification of Tregs (CD3+CD4+CD25hiCD127loFoxP3+), Bregs (CD19 +CD5 +CD1d hiIL-10+), Immature cells (CD19+CD24hi 38hi) and B 10 cells (CD19+CD24hiCD27+), each expressed as percentage of T and B cells.Each lymphocyte population was analysed at baseline, 2 and 6 months after initiation of immunosuppression. Regulatory cells between groups was analysed by Mann Whitney U test and within groups by Wilcoxon signed rank test and Freidman’s test, as applicable.

Results

Bregs were significantly decreased compared to HC at baseline (p =0.002). With immunosuppression, Bregs showed significant increase at 2 and 6 months (p=0.03). Bregs in responders showed an increasing trend at 2 and 6 months (p=0.05), while they did not in non-responders (p=0.247). The increase in Bregs did not significantly differ between different immunosuppressive regimens given. At baseline, Bregs in responders and non- responders were not significantly different. Immature cells and B10 cells were significantly higher compared to HC (p<0.001).Tregs did not differ significantly from HC and did not show significant increase at 2 and 6 months, in both responders and non-responders.

Conclusion

We observed that Breg populations in treatment-naïve LN were significantly reduced compared to HC and increased significantly with immunosuppression. Responders had a trend toward increase in Bregs over time, whereas non-responders did not.

Bregs in HC and LN